NCT05522439View on ClinicalTrials.gov

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

December 22, 2022

Primary Completion Date

September 12, 2024

Study Completion Date

September 12, 2024

Conditions
Asthma With Eosinophilic Phenotype
Interventions
DRUG

SHR-1703

SHR-1703 will be administered by SC injection.

DRUG

SHR-1703 Placebo

Matching Placebo will be administered by the SC route.

Trial Locations (1)

610041

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY